Even though mutations in other RAS isoforms, including the neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) and Harvey rat sarcoma viral oncogene homolog (HRAS) are prevalent in many cancer types, mutations in KRAS account for 85% of all RAS isoform mutations [1,3]. This evidence concerns the gene HRAS and cancer.